Alkem Laboratories Limited — PPTs, 19-03-2025: Investor Presentation

1. **Financial Performance**: Alkem Laboratories reported a total revenue from operations of ₹33,743 million for Q3FY25, marking a year-over-year growth of 1.5%. Domestic sales contributed ₹23,649 million, reflecting a 5.9% growth, while international sales decreased by 6.2% to ₹9,605 million. The EBITDA stood at ₹7,594 million with a margin of 22.5%, improving from 21.3% in the same quarter last year. Net profit after minority interest rose to ₹6,258 million, a 5.2% increase. For 9MFY25, total revenue reached ₹98,208 million, a modest growth of 0.9%. Notably, net profit for this period grew by 23.8% to ₹18,596 million, underscoring strong performance amidst challenges.

2. **Future Outlook and Growth Drivers**: Management indicated optimism about domestic growth outpacing the overall Indian Pharmaceutical Market (IPM), supported by a robust product pipeline and market expansion initiatives, particularly in chronic therapy segments. They aim to leverage their strong R&D capabilities and extensive distribution network for future launches.

3. **Order Book and Operational Updates**: Alkem's operational strength includes recent USFDA approvals, signaling continued focus on expanding its international presence. The company aims to fortify its product portfolio and has filed 179 ANDAs, with 154 approvals granted.

4. **Analyst Q&A Insights**:

- **Revenue and Profitability**: Analysts sought clarification on revenue growth expectations, highlighting that domestic sales are bolstered by expanded field force efforts, while international markets are facing pricing pressures.

- **Market Position and Competitive Landscape**: Management emphasized their competitive edge in chronic therapies and the objective to expand market share through new launches.

- **Operational Challenges or Risks**: Supply chain and cost pressures were addressed, with management confident in mitigating these via efficient practices.

- **Capex and Capital Allocation**: Analysts questioned future capital allocation; management reiterated their commitment to balancing R&D investments while maintaining a healthy cash position of ₹47 billion.

- **Strategic Priorities and Long-Term Vision**: Focus on innovation in biosimilars and generics was shared, aligning with market trends toward integrated healthcare solutions.

5. **Market or Regulatory Updates**: There were no significant regulatory changes impacting Alkem’s operations highlighted in the call; however, the competitive landscape remains a focal point with continued efforts on compliance and quality assurance.

6. **Strategic Focus Areas**: Alkem’s leadership highlighted their strong presence in both the domestic and international markets, emphasizing innovation, product development, and a proactive approach to maintain market leadership in key therapeutic areas.

7. **Investor Insight**: Based on the solid financial health, growth trajectory, and strategic initiatives discussed, Alkem appears to be in a strong position to weather market fluctuations and capitalize on growth opportunities, suggesting a favorable view for investor positioning.